source
- Erasca reports early trial shows tumor shrinkage in 40% of pancreatic and 62% of lung cancer patientsErasca announced that its experimental RAS-targeting oral drug, ERAS-0015, produced tumor reductions in a portion of patients with advanced pancreatic cancer and advanced non-small cell lung cancer…
- Erasca releases early-stage RAS drug data amid legal dispute with Revolution MedicinesErasca has released early-stage data on its RAS-targeting compound, doing so after receiving a legal threat from rival Revolution Medicines. Revolution recently announced a new drug that revived h…